Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot study

Hepatology

Volumn 23, Issue 6, 1996, Pages 1464-1467

  Laurin, Jacqueline ^a   Lindor, Keith D ^a   Crippin, Jeffrey S ^a   Gossard, Andrea ^a   Gores, Gregory J ^a   Ludwig, Jurgen ^a   Rakela, Jorge ^a   McGill, Douglas B ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CHOLESTEROL; CLOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATTY LIVER; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANTILIPEMIC AGENTS; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; CLOFIBRATE; DRUG EVALUATION; FATTY LIVER; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GASTROINTESTINAL AGENTS; HEPATITIS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; URSODEOXYCHOLIC ACID;

EID: 84933047295     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510230624     Document Type: Article

References (26)

1. Ludwig J, Viggiano TR, McGill DB, Ott BJ. Nonalcoholic steatohepatitis. Mayo Clinic experience with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
2. Powell EE, Cooksley WGE, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. HEPATOLOGY 1990;11:74-80.
3. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989;20:594-598.
4. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994;107:1103-1109.
5. Massarrat S, Jordan G, Sahrhage G, Korb G, Bode JC, Dölle W. Five-year follow-up study of patients with nonalcoholic and nondiabetic fatty liver. Acta Hepatogastroenterol 1974;21:176-186.
6. Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study. Int J Obesity 1984;8:97-106.
7. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650-654.
8. Diehl AM, Goodman Z, Ishak KG. Alcohol like liver disease in nonalcoholics: a clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-1062.
9. Cairns SR, Peters TJ. Biochemical analysis of hepatic lipid in alcoholic and diabetic and control subjects. Clin Sci 1983;65:645-652.
10. Eisele JW, Barker EA, Smuckler EA. Lipid content in the liver of fatty metamorphosis of pregnancy. Am J Pathol 1975;81:545-560.
11. Mavrelis PG, Ammon HV, Gleysteen JJ, Komorowski RA, Charaf UK. Hepatic free fatty acids in alcoholic liver disease and morbid obesity. HEPATOLOGY 1983;3:226-231.
12. Cairns SR, Kark AE, Peters TJ. Raised hepatic free fatty acids in a patient with acute fatty liver after gastric surgery for morbid obesity. J Clin Pathol 1986;39:647-649.
13. Acosta D, Wenzel DG. Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells. Atherosclerosis 1974;20:417-426.
14. Schlömerich J, Becher M-S, Schmidt K, Schubert R, Kremer B, Feldhaus S, Gerok W. Influence of hydroxylation and conjugation of bile salts on their membrane-damaging properties: studies on isolated hepatocytes and lipid membrane vesicles. HEPATOLOGY 1984;4:661-666.
15. Heller FR, Martinet JP, Henrion J, Schapiro M, Gallez JF. The rationale for using ursodeoxycholic acid in chronic liver disease. Acta Gastroenterol Belg 1990;53:402-408.
16. Brown DF. The effect of ethyl alpha-p-chlorophenoxy isobutyrate on ethanol-induced hepatic steatosis in the rat. Metabolism 1966;15:868-873.
17. Metropolitan height and weight tables. New York: Metropolitan Life Insurance Co., 1983.
18. Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis 1986;8:283-298.
19. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. HEPATOLOGY 1990;12:1106-1110.
20. Eriksson S, Eriksson K, Bondesson L. Nonalcoholic steatohepatitis in obesity: a reversible condition. Acta Med Scand 1986;220:83-88.
21. Palmer M, Shaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-1413.
22. Andersen T, Gloud C, Franzman MB, Christofferson P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-229.
23. MacCuish AC, Munro JF, Duncan LJP. Follow-up study of refractory obesity treated by fasting. Br Med J (Clin Res) 1968;1:91-92.
24. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994;106:1284-1290.
25. Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Zuin M. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989;34:59S-65S.
26. Leuschner U, Leuschner M, Sieratzki J, Kurtz W, Hubner K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up: a pilot study. Dig Dis Sci 1985;30:642-649.